oncnursingnews1h
Tislelizumab Plus Chemotherapy Demonstrates Strong Anti-Tumor Activity in ESCC
The phase 3 RATIONALE-306 study found no significant difference in overall survival benefits from tislelizumab plus ...
Hosted on MSN24d
BeiGene’s Tevimbra approved in US for first-line gastric cancer treatment
BeiGene has won approval from the US Food and Drug Administration for its PD-1 inhibitor Tevimbra (tislelizumab) in combination with chemotherapy to treat advanced gastric or gastroesophageal ...
Hosted on MSN10mon
Advanced Esophageal Cancer Patients Have a New Hopeful Therapy Option, The Immunotherapy Drug Tislelizumab
This new drug belongs to a class of immunotherapy agents and is called Tislelizumab-jsgr (brand name Tevimbra). If you or a loved one has been diagnosed with stage IV esophageal cancer ...
Morningstar28d
TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy
New indication based on results from a global Phase 3 trial demonstrating TEVIMBRA plus chemotherapy significantly improved overall survival for patients with advanced gastric cancers Second FDA ...
Pharm Exec22d
FDA Approves BeiGene’s Tevimbra for Unresectable or Metastatic HER2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma
Approval of Tevimbra was supported by the RATIONALE-305 Phase III trial, which demonstrated a significant overall survival benefit in patients with unresectable or metastatic HER2-negative gastric or ...
Seeking Alpha28d
BeiGene wins FDA nod for Tevimbra in gastric cancer
BeiGene (NASDAQ:BGNE) announced Friday that the U.S. Food and Drug Administration (FDA) approved its cancer medicine Tevimbra (tislelizumab-jsgr) in combination with chemotherapy as a first-line ...
Pharmaceutical Technology24d
Tevimbra by BeiGene for Urethral Cancer: Likelihood of Approval
Tevimbra is under clinical development by BeiGene and currently in Phase I for Urethral Cancer. According to GlobalData, Phase I drugs for Urethral Cancer does not have sufficient historical data to ...
Pharmabiz25d
US FDA approves BeiGene’s Tevimbra in combination with chemotherapy for first-line treatment of gastric and gastroesophageal junction cancers
San Mateo, California Monday, December 30, 2024, 18:00 Hrs [IST] ...
BeiGene announces FDA approval of Tevimbra
BeiGene (BGNE), a global oncology company that intends to change its name to BeOne Medicines, announced the U.S. FDA has approved Tevimbra in ...
MarketWatch28d
BeiGene Stomach-Cancer Treatment Gets FDA Approval, Second in U.S.
BeiGene said U.S. regulators had approved its Tevimbra to treat a form of stomach cancer. The oncology company said the Food and Drug Administration approved Tevimbra in combination with platinum ...
Cure Today28d
FDA Approves Tevimbra Plus Chemo for Gastric, Gastroesophageal Junction Adenocarcinoma
Tevimbra approved for HER2-negative gastric or gastroesophageal junction adenocarcinoma with PD-L1 expression, in combination with chemotherapy. Phase 3 trial showed Tevimbra improved median overall ...
Yahoo Finance28d
TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy
SAN MATEO, Calif., December 27, 2024--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd ...